1,128 results on '"Kay, Neil E."'
Search Results
2. The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia
3. Defining precancer: a grand challenge for the cancer community
4. Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications
5. Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitors in chronic lymphocytic leukaemia
6. Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL)
7. IκBε deficiency accelerates disease development in chronic lymphocytic leukemia
8. Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia
9. Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism
10. Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis
11. Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis
12. Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia
13. Relationship among three common hematological premalignant conditions
14. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS
15. Mortality Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis
16. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
17. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
18. Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?
19. Progression and survival of MBL: a screening study of 10 139 individuals
20. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
21. Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia
22. CLL update 2022: A continuing evolution in care
23. Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry.
24. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma
25. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity
26. Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis
27. Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans
28. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
29. The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis
30. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
31. Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?
32. Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families
33. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia
34. Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis
35. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy
36. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
37. B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells
38. Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia
39. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia
40. The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites
41. Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
42. Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL)
43. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
44. Chronic lymphocytic leukemia in 2020: a surfeit of riches?
45. Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?
46. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia
47. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations
48. Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia
49. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
50. Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.